Study Overview
This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.
Description
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Official Title
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis
Quick Facts
Study Start:2019-12-16
Study Completion:2030-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
| Inclusion Criteria | Exclusion Criteria |
|---|
| |
Contacts and Locations
Study Locations (Sites)
University of Alabama
Birmingham, Alabama, 35294
United States
The University of Arizona Cancer Center
Tucson, Arizona, 85724
United States
City of Hope
Duarte, California, 91010
United States
University of Southern California
Los Angeles, California, 90033
United States
Hoag Family Cancer Institute
Newport Beach, California, 92663
United States
Blood Cancer Center
Denver, Colorado, 80218
United States
University of Florida Health Shands Cancer Hospital
Gainesville, Florida, 32608
United States
University of Miami
Miami, Florida, 33136
United States
Emory University
Atlanta, Georgia, 30322
United States
University of Chicago
Chicago, Illinois, 60637
United States
University of Maryland
Baltimore, Maryland, 21201
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
University of Minnesota
Minneapolis, Minnesota, 55455
United States
Washington University of Medicine
Saint Louis, Missouri, 63110
United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601
United States
Montefiore Cancer Center
Bronx, New York, 10461
United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263
United States
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States
Weill Cornell Medical Center
New York, New York, 10065
United States
Duke Cancer Institute
Durham, North Carolina, 27710
United States
Ohio State University
Columbus, Ohio, 43210
United States
Tri-Star Centennial Medical Center
Nashville, Tennessee, 37203
United States
Vanderbilt University
Nashville, Tennessee, 37232
United States
MD Anderson Cancer Center
Houston, Texas, 77054
United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84112
United States
University of Virginia Cancer Center
Charlottesville, Virginia, 22903
United States
University of Washington - Fred Hutchinson Cancer Center
Seattle, Washington, 98109
United States
Collaborators and Investigators
Sponsor: Sumitomo Pharma America, Inc.
Study Record Dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
Study Start Date2019-12-16
Study Completion Date2030-04-30
Study Record Updates
Study Start Date2019-12-16
Study Completion Date2030-04-30
Terms related to this study
Additional Relevant MeSH Terms